Q-omics provides the consensus-scored DLX5 profile across patient tissues and cancer cell-line models. DLX5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DLX5 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, DLX5 RNA expression shows 15,661 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where DLX5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DLX5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DLX5 survival associations across molecular data types. DLX5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DLX5 RNA expression–survival associations across cancer types. High DLX5 expression shows unfavorable associations in UVM, KIRP, MESO and STAD, but favorable associations in UCEC and LUSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for DLX5 RNA expression.
This table summarizes DLX5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DLX5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DLX5 shows higher tumor expression in HNSC, KIRC, LUSC, LUAD, LIHC and UCEC. The HNSC box plot shows higher DLX5 RNA expression in tumor versus normal tissue (log2 FC = +2.913, t-test p < 0.001).
This table shows molecular features associated with DLX5 in patient tissues and cancer cell lines. In patient samples, DLX5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DLX5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LUNG_SCLC.
